In terms of treatment choice and outcomes, despite the very small numbers not powered to test for any difference nor to try valid estimations, we report a 6-month median PFS with front-line targeted treatments in patients with compound actionable mutations, which is quite low compared to the pivotal data of TKIs in EGFR-, ALK-, ROS1- and BRAF-mutated NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.